Clinical Trials
Our Research Centers
We offer clinical trial research opportunities at our Queens and Manhattan offices, ensuring convenience for patients across New York City. By participating in these studies, patients gain access to cutting-edge treatments while contributing to advancements in allergy and immunology care.
Lilly ADJoy – Lebrikizumab, Eczema Study
Lebrikizumab is a systemic, novel, subcutaneously injected IgG4 monoclonal antibody selectively targeting Interleukin-13 with high binding affinity and slow off-rate, as demonstrated by efficacy and safety in patients with moderate-to-severe AD in clinical studies.
Primary Objective: To assess real-world effectiveness as the proportion of participants who achieve clear or almost clear skin after 24 weeks of therapy.
PPD & Eli Lilly – Lebrikizumab, Nasal Polyps Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3
Efficacy and Safety Study of Lebrikizumab in Participants with Chronic Rhinosinusitis with Nasal Polyps on a Background Therapy with Intranasal Corticosteroids.
Primary Objective: To evaluate the efficacy of lebrikizumab 250mg Q2W compared to Placebo in reducing nasal congestion severity and endoscopic NPS on background INCS at Week 24.
Novartis REASSERT - Remibrutinib
Remibrutinib is an oral, highly selective Brutons Tyrosine Kinase inhibitor (BTKI) that blocks BTK-medicated degranulation of mast cells and basophils downstream of high-affinity IgE receptor (FcεRI,). In two Phase 3 placebo-controlled studies, remibrutinib demonstrated a fast (as early as week 1) and sustained improvement of Chronic urticaria symptoms (up to week 52).
Primary Objective: Evaluate the 12-week Real-world effectiveness of remibrutinib in adult patients diagnosed with Chronic spontaneous urticaria (CSU) who remain inadequately controlled despite sdH1-Ahs (including all patients who initiate remibrutinib, regardless of prior treatment).
We have been approved as a site and will begin enrollment in 2026!
ADjoy
Title: A Prospective Observational Cohort Study Evaluating Lebrikizumab Therapy in the Management of Adult and Pediatric Participants 12 Years of Age and Older
Sponsor: Eli Lilly and Company
Description: This Phase 4 observational study evaluates the real-world use, safety, and outcomes of lebrikizumab (EBGLYSS) in adults and adolescents (12+) with moderate-to-severe atopic dermatitis across multiple sites in North America, with data collected during routine treatment visits.
Click here to learn more
NOVELTY
Title: Observational study of obstructive lung disease (NOVELTY) – NOVELTY
Sponsor: AstraZeneca
Description: This global observational study aims to better understand and classify severe asthma and COPD, ultimately improving personalized treatments.
PROSE
Title: Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)
Sponsor: Regeneron Pharmaceuticals
Description: This study evaluates the effectiveness of Dupilumab, a monoclonal antibody, in treating chronic sinusitis with nasal polyps.
RAPID
Title: Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
Sponsor: Regeneron
Description: This trial investigates rapid-onset therapies for managing severe allergic reactions, providing faster relief to patients.
GALDERMA
Title: Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Sponsor: Galderma
Description: Focused on skin conditions, this trial evaluates innovative treatments for chronic inflammatory skin issues.
AZ RANS
Title: RANS. Study in Patients with Severe Eosinophilic Asthma and Nasal Polyps. – RANS
Sponsor: AstraZeneca
Description: This trial investigates rapid-onset therapies for managing severe allergic reactions, providing faster relief to patients.
Eosinophilic Esophagitis
Title: Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Sponsor: Regeneron Pharmaceuticals
Description: Aimed at assessing the safety and efficacy of Dupilumab for patients with eosinophilic esophagitis.
ANDHI
Title: A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)
Sponsor: AstraZeneca
Description: This study evaluates the safety and effectiveness of Benralizumab, a monoclonal antibody targeting eosinophils, in reducing exacerbations and improving asthma control in patients with severe, uncontrolled asthma.